Immunosignature

Last updated

Immunosignaturing is a medical diagnostic test which uses arrays of random-sequence peptides to associate antibodies in a blood sample with a disease.

Contents

How it works

Random Peptide Array

Early immunosignature tests used glass microscope slides, with spots of 10,000 random peptides. [1] Newer immunosignature work is run on wafers made of silicon dioxide, with each wafer cut into standard slide size and spotted with 330,034 peptides; [2] however, further description will focus on the glass slide experiments. These random-sequence peptides, 20 amino acids long, are chemically attached to the slides. [1] Of the 20 amino acid length, 3 amino acids (at the C-terminus side of the peptide) are common to each peptide spot. This 3 amino acid segment is used as the linker by which the 17 amino acid chain ("17-mer") is attached to the slide. [1] The 17-mer is the "random peptide", with a random sequence selected by the use of a random number generator. [3] This randomness makes the immunosignature technology different from existing technology to identify disease states via biomarkers, because the 10,000 unique, random peptides per slide are not specifically selected for containing particular sequences. [3] The random sequences are not selected for containing known epitopes, or antibody binding sites, of pathogens. When a sample of diluted blood serum (containing antibodies) is applied to the surface of the peptide microarray, the 17-mers are long enough that there are multiple potential epitopes on each individual peptide. [1]

Antibody Binding

Antibodies are present in the diluted serum sample, and are considered significant to the health of the patient, because if antibodies remain present even in the diluted serum sample, they must reasonably have been present at relatively high amounts in the blood of the patient. [3] This collection of antibodies will bind to regions of some of the random sequence peptides. The antibodies in the serum sample will vary among patients, depending on their health or disease state. [3] Once antibodies have been allowed to bind to the peptides on the microarray, the array is washed (to remove any unbound serum particles or antibodies). [3] After washing, the array now has the 10,000 random peptides, and an unknown number of antibodies bound to some of those peptides.

Antibody Detection

To detect those human antibodies, the array is covered with a solution of a fluorescently labeled secondary antibody. [3] This secondary antibody binds to the patient antibody already on the array from the diluted serum sample, and since this secondary antibody is fluorescently labeled, it is detectable using fluorescence microscopy. [3] After the microarray is washed to remove unbound secondary antibody, and dried via centrifugation, it is scanned using fluorescence microscopy, and the pattern of peptide spots with bound antibodies versus those without antibodies becomes visible. This pattern is called the immunosignature. [3]

Medical applications

Immunosignaturing has many applications in current medical research and testing, such as diagnosing valley fever infections and determining if a vaccine will be effective at protecting patients from disease.

Valley Fever Diagnosis

In the American southwest, where fungal infections of valley fever are a problem, the immunosignature platform has been tested as a way to detect infection in patients. Valley fever infections, when symptomatic, appear similar to the common flu, progressing to pneumonia-like symptoms. [4] Current valley fever testing is unreliable, especially in patients with other infections (such as HIV), and a confident diagnosis can take weeks. [5] Further complicating this testing, in a slim percent of cases patients do not develop any detectable antibody against the fungus. [4] Current testing can also be invasive and more demanding than an immunosignature array, ranging from a sputum test or blood test, [6] to bronchoscopy [5] (the latter is more invasive in addition to taking longer to get a result). Confounding the issue of valley fever, of the 40% of patients showing symptoms, [7] many will be mis-diagnosed with other conditions or not recognized as infected with valley fever. [4] Using the peptide array, scientists were able to determine a distinct immunosignature for valley fever infections, even when the patients had other respiratory infections as well. The immunosignature was also clearly differentiated from that of healthy patients. [4]

Vaccine Efficacy

Immunosignatures were used to test if the efficacy of a vaccine could be predicted (in mice), using different strains of the influenza virus. Mice were given a seasonal flu vaccine, or a vaccine against the specific flu virus tested in the study (PR8). The mice were then infected with the PR8 flu strain. Those groups of mice which were given the PR8-specific vaccine not only survived, but did not display any symptoms of the flu. The mice which received either of the two seasonal flu vaccines all developed flu symptoms, and some (20-40%, depending on which seasonal vaccine received) were killed by the PR8 infection. [8]

The group of mice which received sub-lethal infection doses of PR8, and the group of mice which received vaccines of killed PR8, had different immunosignatures. The two groups of mice immunized with the seasonal flu vaccines also had immunosignatures which were distinct from each other. This demonstrates that the immunosignature platform can be used to distinguish between very similar vaccines. The immunosignature of known protection (here, the signature of mice immunized with the killed virus), was compared to the immunosignatures of the mice groups given less protective vaccines. The more protective a mouse's vaccine was, the closer that mouse's immunosignature was to the protected signature. [8]

Cancer Detection

As the immunosignature platform is useful for any disease which engages the immune system, [9] it was tested to determine if distinct immunosignatures could be determined for various cancers. [3] Using the 10,000 peptide array, comparing against healthy control samples was used to establish immunosignatures for the five different cancers tested. Healthy versus cancer state samples were distinguishable, but there was a slight overlap of the signatures among the cancers. This resulted in a loss of specificity in distinguishing between cancers using immunosignatures. To resolve this, peptides were determined to be statistically significant in the cancer signatures using more stringent selection processes. This eliminated the peptides in common between various cancers, and this selection of peptides was used to distinguish between the cancers, with 95% specificity. [3]

Patent and commercialization

Patent: "Compound Arrays for Sample Profiling", WO 2,010,148,365, inventor(s): Johnston, Stephen A; Stafford, Phillip.

HealthTell acquired the Immunosignature patent in 2012 and is commercializing the human diagnosis capabilities using high throughput manufacturing. For more information: http://www.healthtell.com/

Related Research Articles

<span class="mw-page-title-main">Typhoid fever</span> Disease caused by the bacteria Salmonella Typhi

Typhoid fever, also known simply as typhoid, is a disease caused by Salmonella enterica serotype Typhi bacteria, also called Salmonella typhi. Symptoms vary from mild to severe, and usually begin six to 30 days after exposure. Often there is a gradual onset of a high fever over several days. This is commonly accompanied by weakness, abdominal pain, constipation, headaches, and mild vomiting. Some people develop a skin rash with rose colored spots. In severe cases, people may experience confusion. Without treatment, symptoms may last weeks or months. Diarrhea may be severe, but is uncommon. Other people may carry it without being affected, but are still contagious. Typhoid fever is a type of enteric fever, along with paratyphoid fever. Salmonella enterica Typhi is believed to infect and replicate only within humans.

<span class="mw-page-title-main">DNA vaccine</span> Vaccine containing DNA

A DNA vaccine is a type of vaccine that transfects a specific antigen-coding DNA sequence into the cells of an organism as a mechanism to induce an immune response.

<span class="mw-page-title-main">Coccidioidomycosis</span> Fungal infection

Coccidioidomycosis, commonly known as cocci, Valley fever, as well as California fever, desert rheumatism, or San Joaquin Valley fever, is a mammalian fungal disease caused by Coccidioides immitis or Coccidioides posadasii. Coccidioidomycosis is endemic in certain parts of the United States in Arizona, California, Nevada, New Mexico, Texas, Utah, and northern Mexico.

<span class="mw-page-title-main">Biochip</span> Substrates performing biochemical reactions

In molecular biology, biochips are engineered substrates that can host large numbers of simultaneous biochemical reactions. One of the goals of biochip technology is to efficiently screen large numbers of biological analytes, with potential applications ranging from disease diagnosis to detection of bioterrorism agents. For example, digital microfluidic biochips are under investigation for applications in biomedical fields. In a digital microfluidic biochip, a group of (adjacent) cells in the microfluidic array can be configured to work as storage, functional operations, as well as for transporting fluid droplets dynamically.

Comparative genomic hybridization (CGH) is a molecular cytogenetic method for analysing copy number variations (CNVs) relative to ploidy level in the DNA of a test sample compared to a reference sample, without the need for culturing cells. The aim of this technique is to quickly and efficiently compare two genomic DNA samples arising from two sources, which are most often closely related, because it is suspected that they contain differences in terms of either gains or losses of either whole chromosomes or subchromosomal regions. This technique was originally developed for the evaluation of the differences between the chromosomal complements of solid tumor and normal tissue, and has an improved resolution of 5–10 megabases compared to the more traditional cytogenetic analysis techniques of giemsa banding and fluorescence in situ hybridization (FISH) which are limited by the resolution of the microscope utilized.

Lymphocytic choriomeningitis (LCM) is a rodent-borne viral infectious disease that presents as aseptic meningitis, encephalitis or meningoencephalitis. Its causative agent is lymphocytic choriomeningitis mammarenavirus (LCMV), a member of the family Arenaviridae. The name was coined by Charles Armstrong in 1934.

<span class="mw-page-title-main">Epitope mapping</span> Identifying the binding site of an antibody on its target antigen

In immunology, epitope mapping is the process of experimentally identifying the binding site, or epitope, of an antibody on its target antigen. Identification and characterization of antibody binding sites aid in the discovery and development of new therapeutics, vaccines, and diagnostics. Epitope characterization can also help elucidate the binding mechanism of an antibody and can strengthen intellectual property (patent) protection. Experimental epitope mapping data can be incorporated into robust algorithms to facilitate in silico prediction of B-cell epitopes based on sequence and/or structural data.

<i>Moraxella catarrhalis</i> Species of bacterium

Moraxella catarrhalis is a fastidious, nonmotile, Gram-negative, aerobic, oxidase-positive diplococcus that can cause infections of the respiratory system, middle ear, eye, central nervous system, and joints of humans. It causes the infection of the host cell by sticking to the host cell using trimeric autotransporter adhesins.

The following are notable events in the Timeline of immunology:

<span class="mw-page-title-main">Immunoproteomics</span> Study of large set of protein

Immunoproteomics is the study of large sets of proteins (proteomics) involved in the immune response.

<span class="mw-page-title-main">Influenza</span> Infectious disease

Influenza, commonly known as "the flu" or just "flu", is an infectious disease caused by influenza viruses. Symptoms range from mild to severe and often include fever, runny nose, sore throat, muscle pain, headache, coughing, and fatigue. These symptoms begin from one to four days after exposure to the virus and last for about 2–8 days. Diarrhea and vomiting can occur, particularly in children. Influenza may progress to pneumonia, which can be caused by the virus or by a subsequent bacterial infection. Other complications of infection include acute respiratory distress syndrome, meningitis, encephalitis, and worsening of pre-existing health problems such as asthma and cardiovascular disease.

<span class="mw-page-title-main">Anti-dsDNA antibodies</span> Group of anti-nuclear antibodies

Anti-double stranded DNA (Anti-dsDNA) antibodies are a group of anti-nuclear antibodies (ANA) the target antigen of which is double stranded DNA. Blood tests such as enzyme-linked immunosorbent assay (ELISA) and immunofluorescence are routinely performed to detect anti-dsDNA antibodies in diagnostic laboratories. They are highly diagnostic of systemic lupus erythematosus (SLE) and are implicated in the pathogenesis of lupus nephritis.

<span class="mw-page-title-main">Influenza-like illness</span> Medical diagnosis

Influenza-like illness (ILI), also known as flu-like syndrome or flu-like symptoms, is a medical diagnosis of possible influenza or other illness causing a set of common symptoms. These include fever, shivering, chills, malaise, dry cough, loss of appetite, body aches, nausea, and sneezing typically in connection with a sudden onset of illness. In most cases, the symptoms are caused by cytokines released by immune system activation, and are thus relatively non-specific.

A reverse phase protein lysate microarray (RPMA) is a protein microarray designed as a dot-blot platform that allows measurement of protein expression levels in a large number of biological samples simultaneously in a quantitative manner when high-quality antibodies are available.

Peptide-based synthetic vaccines are subunit vaccines made from peptides. The peptides mimic the epitopes of the antigen that triggers direct or potent immune responses. Peptide vaccines can not only induce protection against infectious pathogens and non-infectious diseases but also be utilized as therapeutic cancer vaccines, where peptides from tumor-associated antigens are used to induce an effective anti-tumor T-cell response.

Immunomics is the study of immune system regulation and response to pathogens using genome-wide approaches. With the rise of genomic and proteomic technologies, scientists have been able to visualize biological networks and infer interrelationships between genes and/or proteins; recently, these technologies have been used to help better understand how the immune system functions and how it is regulated. Two thirds of the genome is active in one or more immune cell types and less than 1% of genes are uniquely expressed in a given type of cell. Therefore, it is critical that the expression patterns of these immune cell types be deciphered in the context of a network, and not as an individual, so that their roles be correctly characterized and related to one another. Defects of the immune system such as autoimmune diseases, immunodeficiency, and malignancies can benefit from genomic insights on pathological processes. For example, analyzing the systematic variation of gene expression can relate these patterns with specific diseases and gene networks important for immune functions.

<span class="mw-page-title-main">Peptide microarray</span>

A peptide microarray is a collection of peptides displayed on a solid surface, usually a glass or plastic chip. Peptide chips are used by scientists in biology, medicine and pharmacology to study binding properties and functionality and kinetics of protein-protein interactions in general. In basic research, peptide microarrays are often used to profile an enzyme, to map an antibody epitope or to find key residues for protein binding. Practical applications are seromarker discovery, profiling of changing humoral immune responses of individual patients during disease progression, monitoring of therapeutic interventions, patient stratification and development of diagnostic tools and vaccines.

<span class="mw-page-title-main">Molecular diagnostics</span> Collection of techniques used to analyze biological markers in the genome and proteome

Molecular diagnostics is a collection of techniques used to analyze biological markers in the genome and proteome, and how their cells express their genes as proteins, applying molecular biology to medical testing. In medicine the technique is used to diagnose and monitor disease, detect risk, and decide which therapies will work best for individual patients, and in agricultural biosecurity similarly to monitor crop- and livestock disease, estimate risk, and decide what quarantine measures must be taken.

<span class="mw-page-title-main">Universal flu vaccine</span> Vaccine that prevents infection from all strains of the flu

A universal flu vaccine is a flu vaccine that is effective against all influenza strains regardless of the virus sub type, antigenic drift or antigenic shift. Hence it should not require modification from year to year. As of 2021 no universal flu vaccine had been approved for general use, several were in development, and one was in clinical trial.

<span class="mw-page-title-main">EpiVacCorona</span> EpiVacCorona vaccine against COVID-19

EpiVacCorona is a peptide-based vaccine against COVID-19 developed by the Russian VECTOR Center of Virology. The lack of protective effectiveness of EpiVacCorona, which is still in use in Russia, has been reported in scientific literature and in the media. The vaccine consists of three chemically synthesized peptides that are conjugated to a large carrier protein. This protein is a fusion product of a viral nucleocapsid protein and a bacterial MBP protein. A phase III clinical trial to show whether or not the vaccine can protect people against COVID-19 was launched in November 2020 with more than three thousand participants. The conclusions and results of the trial have not been made public.

References

  1. 1 2 3 4 Stafford, Phillip; Halperin, Rebecca; Legutki, Joseph Bart; Magee, Dewey Mitchell; Galgiani, John; Johnston, Stephen Albert (2012-04-01). "Physical Characterization of the "Immunosignaturing Effect"". Molecular & Cellular Proteomics. 11 (4): M111.011593. doi: 10.1074/mcp.M111.011593 . ISSN   1535-9476. PMC   3367934 . PMID   22261726.
  2. ↑ O’Donnell, Brian; Maurer, Alexander; Papandreou-Suppappola, Antonia; Stafford, Phillip (2015-06-18). "Time-Frequency Analysis of Peptide Microarray Data: Application to Brain Cancer Immunosignatures". Cancer Informatics. 14 (Suppl 2): 219–233. doi:10.4137/CIn.s17285. ISSN   1176-9351. PMC   4476374 . PMID   26157331.
  3. 1 2 3 4 5 6 7 8 9 10 Stafford, Phillip; Cichacz, Zbigniew; Woodbury, Neal W.; Johnston, Stephen Albert (2014-07-29). "Immunosignature system for diagnosis of cancer". Proceedings of the National Academy of Sciences of the United States of America. 111 (30): E3072–E3080. Bibcode:2014PNAS..111E3072S. doi: 10.1073/pnas.1409432111 . ISSN   0027-8424. PMC   4121770 . PMID   25024171.
  4. 1 2 3 4 Navalkar, Krupa Arun; Johnston, Stephen Albert; Woodbury, Neal; Galgiani, John N.; Magee, D. Mitchell; Chicacz, Zbigniew; Stafford, Phillip (2014-08-01). "Application of Immunosignatures for Diagnosis of Valley Fever". Clinical and Vaccine Immunology. 21 (8): 1169–1177. doi:10.1128/CVI.00228-14. ISSN   1556-6811. PMC   4135907 . PMID   24964807.
  5. 1 2 Ditomasso, John P.; Ampel, Neil M.; Sobonya, Richard E.; Bloom, John W. (February 1994). "Bronchoscopic diagnosis of pulmonary coccidioidomycosis comparison of cytology, culture, and transbronchial biopsy". Diagnostic Microbiology and Infectious Disease. 18 (2): 83–87. doi:10.1016/0732-8893(94)90070-1. PMID   8062536.
  6. ↑ "Valley fever Tests and diagnosis - Mayo Clinic". www.mayoclinic.org. Retrieved 2015-11-12.
  7. ↑ "Valley Fever". Banner Health - www.BannerHealth.com. Retrieved 2015-11-12.
  8. 1 2 Legutki, Joseph Barten; Johnston, Stephen Albert (2013-11-12). "Immunosignatures can predict vaccine efficacy". Proceedings of the National Academy of Sciences of the United States of America. 110 (46): 18614–18619. Bibcode:2013PNAS..11018614L. doi: 10.1073/pnas.1309390110 . ISSN   0027-8424. PMC   3831987 . PMID   24167296.
  9. ↑ "Product Platform | Immunosignature | HealthTell". HealthTell. Retrieved 2015-11-14.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.